Chemotherapy in newborns and preterm babies

Seminars in Fetal and Neonatal Medicine

Volumn 17, Issue 4, 2012, Pages 243-248

  Veal, Gareth J ^a   Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; Dosing; Drug disposition; Infants; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; METHOTREXATE;

CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL PROTOCOL; DEVELOPMENTAL STAGE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG FORMULATION; ETHICS; HUMAN; NEUROBLASTOMA; NEWBORN; PERINATAL DEVELOPMENT; PLASMA CONCENTRATION-TIME CURVE; PREMATURITY; RETINOBLASTOMA; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD DEVELOPMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MEDICAL ONCOLOGY; METHOTREXATE; NEONATOLOGY; NEOPLASMS;

EID: 84862164170     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2012.03.002     Document Type: Review

References (42)

1. Besunder J.B., Reed M.D., Blumer J.L. Principles of drug biodisposition in the neonate (part I). Clin Pharmacokinet 1988, 14:189-216.
2. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology - drug disposition, action and therapy in infants and children. New Engl J Med 2003, 349:1157-1167.
3. Bartelink I.H., Rademaker C.M., Schobben A.F., van den Anker J.N. Guidelines on paediatric dosing on the basis of development physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006, 45:1077-1097.
4. Adamson P.C. It's not easy being small. Pediatr Blood Cancer 2010, 54:341-343.
5. McLeod H.L., Relling M.V., Crom W.R., et al. Disposition of antineoplastic agents in the very young child. Br J Cancer 1992, 18:S23-S29.
6. Thomson P.A., Murry D.J., Rosner G.L., et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2007, 59:847-853.
7. Hempel G., Relling M.V., De R.G., et al. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the Interfant 99 protocol. Pediatr Blood Cancer 2010, 54:355-360.
8. Veal G.J., Cole M., Errington J., et al. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol 2010, 65:1057-1066.
9. van den Berg H., van den Anker J.N., Beijnen J.H. Cytostatic drugs in infants: a review on pharmacokinetic data in infants. Cancer Treat Rev 2012, 38:3-26.
10. Alcorn J., McNamara P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants. Part I. Clin Pharmacokinet 2002, 41:959-998.
11. Blanco J.G., Harrison P.L., Evans W.E., Relling M.V. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000, 28:379-382.
12. Stevens J.C., Hines R.N., Gu C., et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003, 307:573-582.
13. Rhodin M.M., Anderson B.J., Peters A.M., et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Ped Nephrol 2009, 24:67-76.
14. Olkkola K.T., Hamunen K., Maunuksela E.L. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995, 28:385-404.
15. Chay P.C.W., Duffy B.J., Walker J.S. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther 1992, 51:334-342.
16. Hartley R., Green M., Quinn M.W., Rushforth A., Levene M.I. Development of morphine glucuronidation in premature neonates. Neonatology 1994, 66:1-9.
17. Anderson B.J., Holford N.H.G. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009, 24:25-36.
18. Bjorkman S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children. How accurate are available scaling methods?. Clin Pharmacokinet 2006, 45:1-11.
19. Edginton A.N., Schmitt W., Voith B., Willman S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006, 45:683-704.
20. Johnson T.N., Rostami-Hodjegan A., Tucker G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006, 45:931-956.
21. Edginton A.N., Schmitt W., Willman S. Development and evaluation of a generic physiologically-based pharmacokinetic model for children. Clin Pharmacokinet 2006, 45:1013-1034.
22. Sharkey I., Boddy A.V., Wallace H., Mycroft J., Hollis R., Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 2001, 85:23-28.
23. Conroy S., Newman C., Gudka S. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 2003, 14:42-47.
24. Turner S., Nunn A.J., Fielding K., Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999, 88:965-968.
25. Matthay K.K., Reynolds C.P., Seeger R.C., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009, 27:1007-1013.
26. Bauters T.G., Laureys G., Van de Velde V., Benoit Y., Robays H. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. Int J Clin Pharm 2011, 33:597-598.
27. Veal G.J., Cole M., Errington J., et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. Br J Cancer 2007, 96:424-431.
28. Brown W.J., Buist N.R.M., Cory Gipson H.T., Huston R.K., Kennaway N.G. Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet 1982, 1:1250.
29. Cole M., Boddy A.V., Kearns P., et al. The potential clinical impact of carrying out research studies in paediatric oncology: how much do we really know?. Ped Blood Cancer 2006, 46:723-727.
30. Howie S.R. Blood sample volumes in child health research: review of safe limits. Bull WHO 2011, 89:46-53.
31. Harland S.J., Newell D.R., Siddik Z.H., Chadwick R., Calvert A.H., Harrap K.R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 1984, 44:1693-1697.
32. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
33. Newell D.R., Siddik Z.H., Gumbrell L.A., et al. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 1987, 23:1399-1405.
34. Jodrell D.I., Egorin M.J., Canetta R.M., et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992, 10:520-528.
35. Newell D.R., Pearson A.D.J., Balmanno K., et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993, 11:2314-2323.
36. Baker D.L., Schmidt M.L., Cohn S.L., et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New Engl J Med 2010, 363:1313-1323.
37. Picton S.V., Keeble J., Holden V., Errington J., Boddy A.V., Veal G.J. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol 2009, 63:749-752.
38. Chevalier R. Developmental renal physiology of the low birth weight pre-term newborn. J Urol 1996, 156:714-719.
39. Lonnerholm G., Balsecchi M.G., De Lorenzo P., et al. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2009, 52:596-601.
40. Boos J., Krumpelmann S., Schulze-Westhoff P., Euting T., Berthold F., Jurgens H. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?. J Clin Oncol 1995, 13:2954-2960.
41. Urien S., Doz F., Giraud C., et al. Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Cancer Chemother Pharmacol 2011, 67:597-603.
42. Dalle J.H., Wall D., Theoret Y., et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 2003, 32:647-651.